The Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT) addresses existing gaps in the prevention of HIV and other co-infections, especially tuberculosis (TB) and viral hepatitis, among people who inject drugs (PWID). This three-year project was launched in late 2015 with core funding from the European Union (EU), and is being implemented by 23 partners in 18 EU Member States. Twelve collaborating partners are contributing additional expertise, among them the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
HA-REACT MAIN OBJECTIVES
- To significantly contribute to the elimination of HIV and to reductions in cases of TB and viral hepatitis among PWID in the European Union by 2020. This objective is aligned with strategic action plans issued by the European Union, the World Health Organization, UNAIDS and the United Nations Office on Drugs and Crime.
- To focus particularly on Member States where there are obvious gaps in effective and evidence-informed interventions, or where such interventions are not being implemented at a sufficient level.
- To encourage the implementation of comprehensive harm reduction programmes at sufficient scale in all EU Member States as an essential strategy for improving the prevention and treatment of HIV, TB and viral hepatitis.
Find out more abot this Joint Action at hareact.eu